TaiMed Biologics Inc.

As of June 30, 2026, TaiMed Biologics Inc. carries a market capitalization of 17.60B, placing it among publicly traded companies globally. Its enterprise value stands at 16.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TaiMed Biologics Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, TaiMed Biologics Inc. has 270.70M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 28.73, and the price-to-book ratio stands at 4.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 26.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 16.47B versus a market cap of 17.60B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TaiMed Biologics Inc. maintains a current ratio of 15.48, meaning it holds 15.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.01, indicating elevated leverage, while an interest coverage ratio of -3.23 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TaiMed Biologics Inc. posted a negative return on equity (ROE) of -3.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.99, reflecting losses generated across the asset base. The company generates approximately 7.84M in revenue per employee across its workforce of 79.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.41 indicates how many times TaiMed Biologics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, TaiMed Biologics Inc.'s stock has declined approximately 18.53% over the past 52 weeks. The 50-day moving average sits at 62.59, while the 200-day moving average is 57.70.

Over the twelve months ended June 30, 2026, TaiMed Biologics Inc. generated 619.49M in revenue and converted that into -138.90M in net income, yielding earnings per share of -0.51. EBITDA reached -33.64M, while operating income came in at -187.53M.

As of June 30, 2026, TaiMed Biologics Inc. holds 1.61B in cash and equivalents against 478.14M in total debt, resulting in a net debt position of -542.27M. Total book value stands at 3.68B, with working capital of 2.86B providing operational flexibility.

TaiMed Biologics Inc. produced 155.12M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -47.21M in capital expenditures, free cash flow totaled 107.91M - equivalent to 0.39 per share.

Over the twelve months ended June 30, 2026, TaiMed Biologics Inc. posted a gross margin of 45.77, reflecting its pricing power and cost economics. The operating margin of -30.27 and net profit margin of -22.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.61, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.94, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to TaiMed Biologics Inc. shareholders.

TaiMed Biologics Inc.'s most recent stock split took place on February 27, 2024 with a 895:908 split ratio.

As of June 30, 2026, TaiMed Biologics Inc. has an Altman Z-Score of 13.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.